AVC-001
- Generic Name
- AVC-001
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
Phase 1
Terminated
- Conditions
- Renal CancerNon-small Cell Lung CancerProstate CancerTransitional Cell Carcinoma
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 23
- Registration Number
- NCT03927573
- Locations
- 🇩🇪
Klinikum rechts der Isar der TU München, Munich, Bayern, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
🇩🇪Universitätsklinikum Marburg, Marburg, Hessen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath